Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHA1813 vs Investigators' Choice Treatment in High-Grade Meningiomas
NCT07613450Phase 3Not yet recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- May 2026
- Primary completion
- Jul 2029
01
Overview
A Phase 3 trial of SYHA1813 in meningioma, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
SYHA1813
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT07613450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613450.